An interventional study of Computerized Plasticity-Based Adaptive Cognitive Training in Age-related Cognitive Decline, sponsored by Posit Science Corporation. Completed at 2 sites in United States. Open to participants aged 70 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-19.
Sponsored by Posit Science Corporation · Not applicable, Interventional, and Treatment
This study aims to examine the longer-term benefits of a novel, neuroplasticity-based, computerized and web-deliverable training program (PACR-CT) five years from the initial 10 weeks of training from our Phase II study - Protocol #: PSC-0605-17 (Aim 1) and test the interactive effect of previous training and 10 weeks of booster training (Aim 2). Both the study and the software being investigated meet the criteria of Non-Significant Risk.
This study will employ a single arm, open label design with use of the PACR-CT with all participants who completed the Phase II study, as well as approximately 60 new participants (with a goal of 40 completers) who are age-matched and untrained older adults. After consent, only the new, untrained participants will complete the screening visit. Then all participants will perform the pre-training visit (cognitive and functional assessments, MRI/fMRI and blood draw), followed by 10 weeks of training, and then followed by post-training visit (cognitive and functional assessments and MRI/fMRI).
Posit Science Corporation is the lead sponsor of 36 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, up to 5 sessions per week, 42 minutes per session.
Other: Computerized Plasticity-Based Adaptive Cognitive Training
Forty-two minutes of training on computerized exercises that targets processing speed, memory and attention.
Also known as: PACR-CT
Change in performance on global cognitive composite score
Change in performance on global cognitive composite score based on the average of all normalized assessment measures.
Time frame: At 5 years and at 3 months
Change in performance on processing speed composite score
Change in performance on processing speed will be measured using the composite score created by averaging the z-scores of Pattern Comparison, Letter Comparison, and Digit Symbol Coding tasks.
Time frame: At 5 years and at 3 months
Change in performance on working memory
Change in performance on working memory will be measured using the composite score created by averaging the z-scores of Visual Short Term Memory and N-Back Tasks.
Time frame: At 5 years and at 3 months
Changes in performance on episodic memory
Change in performance on episodic memory will be measured using the composite score created by averaging the z-scores of Selective Reminding Task and Face Name Task.
Time frame: At 5 years and at 3 months
Change in performance on executive function
Change in performance on executive function will be measured using the composite score created by averaging the z-scores of Flanker Task and Task Switch (fMRI task).
Time frame: At 5 years and at 3 months
Change in brain function
Change in resting state functional connectivity will be measured by resting State T2\*weighted EPI-BOLD, a 10-minute task-free BOLD contrast sequence consisting of 300 volumes (TR=2000 ms/TE=30ms) at 3.4mm3 in-plane resolution and 3mm slice thickness. Participants will be instructed to keep their eyes open and maintain attention on a central gray fixation cross on a black screen.
Time frame: At 5 years and at 3 months
Change in brain structure
3D T1-Weighted multi-echo MPRAGE. Morphometric analyses will be based on this MRI sequence (not accelerated because the reliability of acceleration for multi-site studies has not yet been established). We will achieve spatial resolution of 1 x 1 x 1 mm voxels.
Time frame: At 5 years and at 3 months
Change in task-related brain activation
Change in functional connectivity and brain activation will be measured while performing Task Switch.
Time frame: At 5 years and at 3 months
Change in functional performance
Between-group magnitude of change in sum time of all tasks in the Timed Instrumental Activities of Daily Living (TIADL). Higher scores indicate greater impairment in functional performance.
Time frame: At 5 years and at 3 months
Change in Depressive Symptoms
Between-group magnitude of change in sum score using the self-report measure, Center for Epidemiologic Studies Depression Scale (CES-D). The scoring range is 0-60. Higher scores indicate the presence of more symptomatology.
Time frame: At 5 years and at 3 months
Blood-based Biomarker for Alzheimer's Disease
Group differences in the P-tau181, Aβ1-42/Aβ1-40 concentrations
Time frame: At 5 years
Change in Stress
Between-group magnitude of change in sum score using the self-report measure, Perceived Stress Scale (PSS-10). The scoring range is 0-40. Higher scores indicate higher perceived stress.
Time frame: At 5 years and at 3 months
Change in Self-Efficacy
Between-group magnitude of change in sum score using the self-report measure, Self-Efficacy Survey. The scoring range is 10-40. Lower scores indicate lower self efficacy.
Time frame: At 5 years and at 3 months
Change in Life Satisfaction
Between-group magnitude of change in sum score using the self-report measure, Life Satisfaction Scale. The scoring range is 5-35. Lower scores indicate lower life satisfaction.
Time frame: At 5 years and at 3 months
Change in Physical Activity
Change in total score based on weekly self-report dairy about physical activity during training period.
Time frame: At 5 years and at 3 months
Change in Diet
Change in total score based on weekly self-report dairy about diet during training period.
Time frame: At 5 years and at 3 months
Change in Social Activity
Change in total score based on weekly self-report dairy about social activity during training period.
Time frame: At 5 years and at 3 months
Change in Sleep
Change in total score based on weekly self-report dairy about sleep during training period.
Time frame: At 5 years and at 3 months
Change in Functional Abilities
Change in total score based on weekly self-report dairy about functional abilities during training period.
Time frame: At 5 years and at 3 months
Ran from Dec 2023 to primary completion in Jan 2026, 25 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.